A phase I/II trial evaluated the IDO1 inhibitor, Epacadostat in combination with pembrolizumab in advanced NSCLC patients who have received platinum-based chemotherapy but no prior immunotherapy. This evidence concerns the gene IDO1 and non-small cell lung carcinoma.